DeepMed Research

Janssen Vaccines & Prevention B.V.

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: -

Established: 2000-01-01

Employees: -

Market Cap: -

Website: http://www.crucell.com

Clinical Trials

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Phase 2

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Biological: Ad26.RSV.preF

First Posted Date: 2017-11-07

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 64

Registration Number: NCT03334695

Locations: 🇬🇧
hVIVO Services Limited, London, United Kingdom

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Phase 1

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Biological: Ad26.Mos4.HIV
Biological: MVA-Mosaic
Biological: Clade C gp140 + Mosaic gp140
Drug: Placebo

First Posted Date: 2017-10-12

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 25

Registration Number: NCT03307915

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

Phase 1

Completed

Conditions: Respiratory Syncytial Viruses
Respiratory Tract Infections

Interventions: Biological: Ad26.RSV.preF (1*10^11 vp)
Drug: Placebo
Biological: Ad26.RSV.preF (5*10^10 vp)

First Posted Date: 2017-10-06

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 48

Registration Number: NCT03303625

Locations: 🇺🇸
Heartland Research Associates, LLC, Newton, Kansas, United States
🇫🇮
Järvenpään rokotetutkimusklinikka, Järvenpää, Finland
🇫🇮
University of Tampere/Vaccine Research Center, Turku, Finland

and more 3 locations

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Phase 2

Terminated

Conditions: HIV-1

Interventions: Biological: Ad26.Mos4.HIV
Biological: Placebo
Biological: Clade C gp140

First Posted Date: 2017-02-23

Last Posted Date: 2023-04-18

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 2636

Registration Number: NCT03060629

Locations: 🇿🇦
Masiphumelele Research Centre, Cape Town, South Africa
🇿🇼
St Mary's Clinic, Chitungwiza, Zimbabwe
🇲🇼
UNC Lilongwe Project, Lilongwe, Malawi

and more 18 locations

A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: cIPV
Biological: sIPV

First Posted Date: 2017-01-26

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 32

Registration Number: NCT03032588

Locations: 🇧🇪
Center for Vaccinology (CEVAC), Gent, Belgium

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Biological: Ad26.Mos4.HIV
Biological: Clade C gp140/Mosaic gp140 plus adjuvant
Biological: gp140 HIV Bivalent Vaccine
Biological: Clade C gp140 plus adjuvant

First Posted Date: 2016-10-17

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 155

Registration Number: NCT02935686

Locations: 🇺🇸
Bridge HIV, San Francisco, California, United States
🇺🇸
The Hope Clinic at Emory University, Decatur, Georgia, United States
🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States

and more 10 locations

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Ad26.RSV.preF 1*10^11 vp
Biological: Ad26.RSV.preF 5*10^10 vp
Drug: Placebo

First Posted Date: 2016-10-06

Last Posted Date: 2019-02-19

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 73

Registration Number: NCT02926430

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

Phase 1

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Biological: Ad26.Mos.HIV
Drug: Placebo
Biological: MVA-Mosaic

First Posted Date: 2016-09-29

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 27

Registration Number: NCT02919306

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Ad26.Filo
Biological: Ad26.ZEBOV
Biological: MVA-BN-Filo
Biological: Placebo

First Posted Date: 2016-08-09

Last Posted Date: 2018-02-05

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 72

Registration Number: NCT02860650

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Biological: Ad26.Mos.HIV
Biological: Ad26.Mos4.HIV
Biological: Clade C gp140

First Posted Date: 2016-06-02

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Vaccines & Prevention B.V.

Target Recruit Count: 201

Registration Number: NCT02788045

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy